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Treatment of severe acute respiratory
syndrome with lopinavir/ritonavir: a
multicentre retrospective matched
cohort study
Objectives. To investigate the possible benefits and adverse effects of the addition
of lopinavir/ritonavir to a standard treatment protocol for the treatment of severe
acute respiratory syndrome.
Design. Retrospective matched cohort study.
Setting. Four acute regional hospitals in Hong Kong.
Patients and methods. Seventy-five patients with severe acute respiratory
syndrome treated with lopinavir/ritonavir in addition to a standard treatment
protocol adopted by the Hospital Authority were matched with controls retrieved
from the Hospital Authority severe acute respiratory syndrome central database.
Matching was done with respect to age, sex, the presence of co-morbidities,
lactate dehydrogenase level and the use of pulse steroid therapy. The 75 patients
treated with lopinavir/ritonavir were divided into two subgroups for analysis:
lopinavir/ritonavir as initial treatment, and lopinavir/ritonavir as rescue therapy.
These groups were compared with matched cohorts of 634 and 343 patients,
respectively. Outcomes including overall death rate, oxygen desaturation,
intubation rate, and use of pulse methylprednisolone were reviewed.
Results. The addition of lopinavir/ritonavir as initial treatment was associated
with a reduction in the overall death rate (2.3%) and intubation rate (0%), when
compared with a matched cohort who received standard treatment (15.6% and
11.0% respectively, P<0.05) and a lower rate of use of methylprednisolone at a
lower mean dose. The subgroup who had received lopinavir/ritonavir as rescue
therapy, showed no difference in overall death rate and rates of oxygen
desaturation and intubation compared with the matched cohort, and received a
higher mean dose of methylprednisolone.
Conclusion. The addition of lopinavir/ritonavir to a standard treatment protocol
as an initial treatment for severe acute respiratory syndrome appeared to be
associated with improved clinical outcome. A randomised double-blind placebo-
controlled trial is recommended during future epidemics to further evaluate this
treatment.
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Introduction
Severe acute respiratory syndrome (SARS) has created
global alarm, with significant impact on the health care and
economy of affected areas. At the time of writing, at least
30 regions had been affected with over 8099 probable
cases and 774 deaths.1 The intubation rate for patients
with SARS in many centres was over 20%,2,3 and the overall
case fatality rate was 9.6%.1 Both human and animal
studies have now confirmed that SARS is caused by a novel
coronavirus (SARS-CoV),4-6 satisfying Koch’s postulations
for causation.7,8
In the early days of the epidemic, histopathological
changes in lung tissue from patients suggested a viral
aetiology possibly associated with immuno-dysregulation
in pathogenesis as evident by the pronounced activation of
macrophages within the alveoli.9 Various treatment regimens
were recommended for SARS, ranging from supportive
therapy to intensive immunomodulation by corticosteroids,
with the majority being empirical.2,3,10-12 Before SARS-CoV
was identified as the causative agent, ribavirin, a purine
nucleoside analogue which prevents replication of a large
number of RNA and DNA viruses, was suggested for
treatment in view of its broad spectrum activity.2,13
Based on this theoretical background and the low fatality
rate reported in early cases,2,10 the combination of corti-
costeroid and ribavirin therapy was adopted by the Hospital
Authority of Hong Kong (HA) as the interim standard
treatment in the early phase of the SARS epidemic.14 With
isolation of SARS-CoV, in vitro anti-viral susceptibility
testing demonstrated that the virus was inhibited by
ribavirin at a level which was difficult to achieve in the
clinical setting.15 As the epidemic progressed, the case
fatality rate in Hong Kong was projected to be around 13%
for patients younger than 60 years and 43% for patients aged
60 years or older,16 indicating an urgent need to find an
effective therapy.
A previous prospective study of the clinical progression
of SARS and the viral load of patients demonstrated a
progressive increase in viral load in the respiratory tract,
reaching a peak in the second week of the illness.17 The
results implied a window period of lower viral load during
which anti-viral therapy might confer significant clinical
benefit. A number of treatment modalities, including anti-
viral peptides inhibiting viral fusion, anti-sense RNA, and
immunomodulators have been suggested. However, these
options are not clinically available at the time of writing.
Among the licensed anti-viral drugs screened in our
laboratory, lopinavir was demonstrated to have clinically
relevant in vitro activity against the prototype SARS-CoV
HKU39849; synergism was also demonstrated for
lopinavir and ribavirin.15 Given this information, a number
of physicians in the HA had used lopinavir/ritonavir
(LPV/r) in addition to the standard treatment protocol.
This was given either as an initial treatment, or as a rescue
treatment after failure of standard treatment, as previous
data had suggested patients might have persistently high
viral loads.17 The aim of this study was to analyse retro-
spectively the outcomes of patients with SARS treated
with LPV/r compared with a matched cohort who received
standard treatment only.
Methods
Diagnosis and standard treatment protocol
During the epidemic, all SARS patients were admitted
to HA hospitals as policy. A modified World Health
Organization definition was adopted as the case definition
of probable SARS. This included the presence of the
following: fever of 38ΟC or higher; new radiological in-
filtrates compatible with pneumonia; two of the following:
chills, cough, general malaise, physical signs of lung
consolidation; and the absence of an alternative diagnosis
to explain the clinical presentation. Probable SARS cases
were treated according to the principles of the HA SARS
guideline.10,14,18 These included a trial of broad spectrum
antibiotics, consisting of a combination of a β-lactam plus a
macrolide, or levofloxacin, according to current recom-
mendations.19 As soon as the diagnosis of SARS was
established, ribavirin was given for 10 to 14 days (2.4 g oral
loading dose, followed by 1.2 g orally every 8 hours, or
8 mg/kg intravenously every 8 hours, if the patient could
not tolerate oral treatment), together with a tailing
regimen of corticosteroid therapy for 21 days (starting
dose: hydrocortisone 100-200 mg every 6-8 hours, or methyl-
prednisolone 3 mg/kg/day, depending on severity).10,14,18
If patients developed increasing shortness of breath,
oxygen desaturation, and radiological worsening, pulses
of methylprednisolone 500-1000 mg daily given intra-
venously were used as rescue therapy, if not contra-
indicated.10 Patients were considered for intubation if
they developed acute respiratory distress syndrome (ARDS)
as defined by a partial pressure of arterial oxygen to frac-
tion of inspired oxygen (PaO2/FiO2) ratio of <200 mmHg,20
or had persistent and severe hypoxaemia with oxygen satu-
ration of less than 85%, despite oxygen supplementation.
Lopinavir/ritonavir treatment protocol
From 16 April 2003, physicians from four participating
hospitals (United Christian Hospital, Princess Margaret
Hospital, Tuen Mun Hospital, and Caritas Medical Centre)
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added lopinavir 400 mg/ritonavir 100 mg orally every 12
hours to the above standard regimen after obtaining consent
from patients. Patients with contra-indications, such as pre-
existing liver disease, known hypersensitivity, or who were
pregnant were excluded from treatment with LPV/r.
Approval for off-license use of LPV/r was obtained from
the HA. Lopinavir/ritonavir were given for 10 to 14 days,
depending on disease severity and patient tolerance.
Physicians either gave LPV/r as an initial treatment in
combination with ribavirin for sequential patients newly
diagnosed to have SARS; or it was given as rescue
therapy later in the course of the illness when patients had
worsening oxygen saturation, shortness of breath, and
relevant radiological findings, and after patients were
judged to have failed pulse steroid treatment. In the
latter group, administration of LPV/r may not have been
given concurrently with ribavirin, depending on the time of
the decision to use LPV/r as rescue therapy.
Data collection
A standardised data capture form was developed for
collecting clinical data for all probable SARS cases admitted
to HA hospitals. The information captured included the
following:
(1) important dates (onset of fever, onset of symptoms,
contact with SARS patients, admission, discharge or
death);
(2) presence of pre-defined co-morbidities (asthma,
chronic obstructive pulmonary disease, ischaemic
heart disease, cerebrovascular disease, cancer, diabetes
mellitus, chronic renal failure, and chronic liver
disease);
(3) daily observations of clinical parameters (temperature,
pulse, respiratory rate, bowel movement, oxygen
saturation, fraction of inspired oxygen); and
(4) details of drug treatment, invasive and non-invasive
ventilation.
The clinical information was merged with selected la-
boratory and pharmacy information from the HA central
database.
Patients treated with LPV/r who fulfilled the criteria for
probable SARS were recruited from the four hospitals. Case
matching was performed between the LPV/r-treated
group and the HA standard treatment group. Patients treated
with LPV/r were divided into two subgroups for analysis:
LPV/r as initial treatment and LPV/r as rescue therapy, as
previously described. Matched cohorts, who were treated
with the standard treatment adopted by the HA, were
retrieved from the database for the two subgroups. Matching
was done with respect to the reported prognostic factors for
poor outcome: age, sex, presence of co-morbidities and level
of lactate dehydrogenase (LDH).2,3 Age was matched
according to five defined age-groups (15-24 years, 25-44
years, 45-64 years, 65-84 years, and 85 years or older). Co-
morbidity was matched according to the presence or
absence of significant medical illnesses. Lactate dehydro-
genase was matched according to six defined ranges of
LDH levels (<300 IU/L, 300-399 IU/L, 400-499 IU/L, 500-
699 IU/L, 700-899 IU/L, and ≥900 IU/L).
For the subgroup that received LPV/r as initial treat-
ment, matching with patients who received standard
treatment was performed on four variables—age, sex, co-
morbidity, and the initial LDH level within 5 days of onset
of symptoms. For the subgroup that received LPV/r as
rescue therapy after pulse steroid treatment, matching was
performed on five variables—age, sex, co-morbidity,
maximal LDH level before the administration of pulse
methylprednisolone, and the use of pulse methyl-
prednisolone. Patients with SARS who had received
standard treatment and who matched with the respective
study groups on the relevant prognostic variables
were included as controls. This approach was adopted to
strengthen statistical power and avoid sampling variation
due to random selection of control patients from the
database. The distribution of patients in the two LPV/r-
treated subgroups and their matched cohorts across the
prognostic strata are shown in Tables 1a and 1b.
The following outcomes were compared for each of the
LPV/r-treated subgroups and their matched cohorts: death
rate, percentage of patients with oxygen desaturation
(inability to maintain normal saturation of ≥96% despite
supplemental oxygen), airway intubation rate, and use of
rescue pulse methylprednisolone (proportion and mean
dose). Adverse effects in terms of raised serum transaminase
levels (a three-fold rise in alanine aminotransferase [ALT])
and a raised serum amylase level (two-fold rise) were com-
pared between the treatment subgroups and matched cohorts.
The age-standardised mortality rates for all patients with
SARS aged 15 years or older admitted to the HA during the
epidemic were retrieved. These were then classified into five
cohorts according to their time of symptom onset. We
assessed whether there was a general trend towards declining
mortality through the epidemic as clinical knowledge,
experience and acumen improved.
Statistical analysis
To adjust for the differing distribution of patients across the
prognostic strata between the LPV/r-treated and the standard
treatment group, the direct standardisation method was
employed to compute the standardised outcome rates for
each of the two matched cohorts, which were then compared
with the corresponding crude rates of the LPV/r-treated sub-
groups. The outcome rates for the matched cohorts were
weighed against the proportion of LPV/r-treated cases in
each prognostic stratum as shown in Tables 1a and 1b.
The outcome rates of the LPV/r-treated group were
considered to be significantly different from the respective
matched cohort’s standardised rates if their 95% confidence
intervals (95% CIs) did not overlap. The exact 95% CIs for
binomial variables were calculated for the LPV/r-treated
subgroups whereas the 95% CIs of the directly standardised
Chan et al
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rates for the matched cohorts were approximated using the
method for weighted sums of independent Poisson variables
proposed by Dobson et al.21 Two sample t-tests were used
to test the between-group difference in the mean dose of
pulse methylprednisolone.
Results
The initial database included 1521 probable cases of SARS
who were admitted into HA hospitals. There were 676
males and 845 females, and the mean age was 42.5 years
(standard deviation [SD], 19.5 years). Eighty-one LPV/r-
treated patients were identified from the four centres. Of
the 81 LPV/r-treated patients, five patients did not have
LDH readings at an appropriate time-point and one
patient did not have a matched control, and were therefore
excluded from the analyses. Data from 75 patients were
analysed, and all had microbiological confirmation of SARS-
CoV infection by serology or reverse-transcriptase
polymerase chain reaction (RT-PCR) tests. Among the 75
patients, LPV/r was given as initial therapy to 44 patients
and as rescue therapy to 31 patients. The prognostic profiles
of these patients are reported in Table 2.
For the subgroup that received LPV/r as initial treat-
ment, a total of 634 patients were retrieved from the standard
treatment group as controls after matching on the four
variables of age, sex, co-morbidity, and initial LDH level.
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Table 1b. Matching of the LPV/r rescue treatment group*
* All patients received pulse methylprednisolone
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In this control group, 576 (90.9%) patients had positive
SARS-CoV serological or RT-PCR tests. Treatment with
LPV/r was started at a median of 5.5 days after symptom
onset, and one day after the commencement of ribavirin.
Of the 44 patients who received LPV/r as initial therapy,
30 patients (68.2%; 95% CI, 52.3-81.8) had episodes
of oxygen desaturation and 12 patients (27.3%; 95% CI,
11.4-40.9) were given pulse methylprednisolone. None
were intubated and one patient died (2.3%; 95% CI, 0-6.8).
In the matched cohort, the respective standardised rates for
various outcomes were as follows: oxygen desaturation in
84.5% (95% CI, 74.4-95.2); use of pulse methylprednisolone
in 55.4% (95% CI, 47.6-63.9); intubation in 11.0% (95%
CI, 7.7-15.3); and death in 15.6% (95% CI, 9.8-22.8).
Comparing the 95% CIs of the LPV/r-treated group and
the matched cohort, there was a statistically significant
difference evident in the overall death rate and intubation
rate, with reductions seen with LPV/r treatment. As shown
in Table 3, the mean dose of pulse methylprednisolone
in the subgroup who received LPV/r as initial treatment
was lower (1.6 g; 95% CI, 1.1-2.0) than the matched cohort
(3.0 g; 95% CI, 2.8-3.2). Regarding drug toxicity as
evidenced by a three-fold rise in ALT, there was no signifi-
cant difference in rate between the group who received LPV/r
as initial therapy and the matched cohort (9.1%; 95% CI,
0-18.2 versus 6.9%; 95% CI, 4.5-9.9). Raised serum amylase
levels (a two-fold rise) were reported in 5% (95% CI, 0-15)
in the group given LPV/r as initial treatment compared
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Table 3. Comparison of outcomes for the group given LPV/r as initial treatment and a matched cohort*
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Table 4. Comparison of outcomes of the group given LPV/r as rescue treatment and a matched cohort*
* Matched on age, sex, presence/absence of co-morbidity, lactate dehydrogenase level before pulse methylprednisolone, and use of pulse
* methylprednisolone
† Standardised based on the percentage distribution of subjects of the treated group across the prognostic strata in Table 1
‡ NS  not significant
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with 2.4% (95% CI, 0-4.8) of the matched cohort (non-
significant). No patient in either group had serum amylase
levels greater than 1000 IU/L.
For the LPV/r rescue subgroup, a total of 343 patients
were retrieved from the standard treatment group as
controls after matching of the five variables of age, sex, co-
morbidity, peak LDH level, and the use of pulse methyl-
prednisolone. In this control group, 329 (95.6%) patients
had positive SARS-CoV serological or RT-PCR tests.
Treatment with LPV/r was started at a median of 18 days
after symptom onset, and did not overlap with ribavirin
treatment (median time-lag, 1 day). As shown in Table 4,
there were no significant differences in overall oxygen
desaturation, intubation, and death rates between the
treatment and control groups. The mean dose of pulse
methylprednisolone given was significantly higher (3.8 g;
95% CI, 3.5-4.2) compared with the matched cohort
(3.0 g; 95% CI, 2.9-3.2). Regarding drug toxicity as
evidenced by a three-fold rise in ALT, there was no signi-
ficant difference between the group receiving LPV/r as
rescue therapy and the matched cohort (25.8%; 95% CI,
9.7-41.9 versus 9.1%; 95% CI, 5.8-13.4). Raised serum
amylase levels (two-fold rise) were reported in 11.8 % (95%
CI, 0-29.4) in the LPV/r as rescue treatment group versus
2.6% (95% CI, 0-6) of the matched cohort (not significant).
In the LPV/r as rescue therapy group, one patient was re-
ported to have a serum amylase level greater than 1000 IU/L,
but none was reported in the matched controls. Treat-
ment with LPV/r was discontinued in this affected patient,
with subsequent normalisation of amylase levels.
The age-standardised mortality rates for 1667 SARS
cases aged 15 or more were retrieved from the HA SARS
central database. The rates are reported for the five time
periods according to the dates of symptom onset: 15.0%
for 15 March 2003 or before; 18.1% for 16 to 31 March;
17.8% for 1 to 15 April; 15.1% for 16 to 30 April; and
20.8% for 1 to 31 May. These age-standardised mortality
rates did not suggest a trend towards declining mortality
throughout the epidemic.
Discussion
Genomic analysis of the SARS-associated coronavirus
genome revealed dfferent types of enzymatic targets—the
RNA replicase, and the proteases.22-24 The discovery of a
putative mRNA cap-1 methyltransferase may suggest
another potential target for anti-viral therapy.25 Although a
chemically synthesised cysteine proteinase inhibitor
(E64d),26 a natural salivary cysteine proteinase inhibitor
(cystatin D),27 and a natural serine proteinase inhibitor
(leupeptin)28 are known to inhibit mouse or human
coronaviruses in cell culture systems at low concentrations,
none of these has been used in the treatment of corona-
virus infection in animals or humans.
With respect to nucleoside analogues, success has been
achieved by ribavirin in treating fulminant hepatitis
caused by mouse coronavirus.29 Ribavirin is active against
mouse coronavirus, mostly due to its indirect immuno-
modulatory effect rather than its weak anti-viral activity.29
The only anti-viral agent that has been used against corona-
virus in human is alpha-interferon, which is given intra-
nasally as a prophylaxis rather than a treatment for
common cold.30 Recently, alpha-interferon and beta-
interferon have been shown to inhibit SARS-CoV
in vitro.31 Hitherto, alpha-interferon has not been used in
the treatment of SARS because it is known to be pro-
inflammatory and associated with pulmonary toxicity,
including causing interstitial pneumonitis, and bron-
chiolitis obliterans-organising pneumonia.32 Glycyrrhizin,
an active component of liquorice root, has been found to
inhibit SARS-CoV replication in vitro,33 but no clinical
data are available on its use.
Both lopinavir and ribavirin individually have a
weak in vitro inhibitory effect on the prototype SARS-
CoV. In vitro anti-viral susceptibility testing showed
that the cytopathic effect (CPE) of SARS-CoV was
inhibited by lopinavir at 4 µg/mL and by ribavirin at
50 µg/mL after 48 hours of incubation.15 This is in
keeping with the fact that lopinavir is specific for
aspartate proteases.34 Using the checkerboard assay for
synergy, CPE inhibition was achieved down to a con-
centration of lopinavir 1 µg/mL plus ribavirin 6.25 µg/mL
when the viral inoculum was reduced below 50 TCID50
(tissue culture infectious dose).15 Thus, both peak
(9.6 µg/mL) and trough (5.5 µg/mL)35 serum concen-
trations of lopinavir may inhibit this virus. Synergism
between lopinavir and ribavirin might be a reason for
the relatively large therapeutic benefits seen in this
study, despite the weak anti-viral activities of the in-
dividual drugs. Ritonavir has little in vitro activity
against SARS-CoV, but it inhibits the CYP3A-mediated
metabolism of lopinavir, thereby increasing the serum
drug concentration of lopinavir.
Our results showed that early use of lopinavir/ritonavir
with ribavirin was associated with a reduced use of pulse
methylprednisolone, and a reduction in intubation and
mortality rates. They also showed that this treatment was
not associated with abnormal liver function or with raised
serum amylase levels. These benefits were not evident
in those patients who received LPV/r rescue therapy, ini-
tiated later in the course of the disease when patients had
deteriorated further. It is also noteworthy that patients
who received LPV/r as rescue treatment received higher
doses of pulse corticosteroid, suggesting that physicians
had selected patients for LPV/r rescue therapy who were
in poorer clinical condition. This might have masked
any possible benefits of LPV/r treatment. Furthermore, any
benefit from synergism between the two anti-viral
agents might have been eliminated in the rescue treat-
ment group since ribavirin was already discontinued when
LPV/r was added.
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A previous study on the sequential changes in viral load
and disease progression of SARS suggested that there was
an initial viral replicative phase that led to a maximal viral
load at around day 10. Thereafter, the disease progressed
to ARDS and severe end-organ damage in some patients.11
This suggests that in the treatment of SARS, a reasonable
strategy is to reduce the peak viral load by an effective anti-
viral agent, as this might decrease the need for salvage
therapy with immunosuppressants, and hence reduce the
risk of nosocomial infections.36 Our results are in keeping
with this hypothesis, showing that early use (median, 5.5
days after symptom onset, ie before peak viral replication
at day 10), but not rescue use of LPV/r (median, 18 days
after symptom onset), was beneficial in terms of reduction
in use of pulse corticosteroid therapy, rates of intubation
and death.
Our study was limited in being retrospective, with
patients not randomly assigned to treatment and control
groups. Attempts were made to match all the known
prognostic factors for the LPV/r-treated subgroups and the
controls, however. It is noteworthy that co-morbidities
were not classified according to severity, as this may
have confounded results. Physicians had possibly selected
sicker patients for LPV/r as rescue treatment, as the mean
dose of pulse steroid received prior to LPV/r was higher
for this group than the matched cohort. This might
have masked some of the possible benefits of LPV/r. It is
also possible that the apparent benefits of LPV/r seen
were due to declining mortality towards the end of the
epidemic as clinical experience grew. However, the age-
standardised mortality rates were fairly constant through-
out the epidemic, arguing against this contention.
This study was not designed to evaluate whether
ribavirin and/or steroid therapy are effective treatments for
SARS. Both the LPV/r-treated and the standard treatment
groups were given ribavirin and steroid therapy according
to the same standard protocol. Future studies are needed to
evaluate these drugs separately.
Conclusion
The addition of LPV/r to a standard treatment protocol for
SARS as an initial treatment appeared to be associated
with a significant reduction in the need for rescue pulse
corticosteroid therapy, avoidance of intubation, and a
reduction in mortality rate. A randomised, double-blind,
placebo-controlled trial for the use of anti-viral agents is
recommended during future SARS epidemics to fully
evaluate this potential treatment.
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